Nektar Therapeutics (NKTR) was Resumed by Brean Capital to “Buy”. Brean Capital advised their investors in a research report released on Sep 30, 2016.
On the company’s financial health, Nektar Therapeutics reported $-0.36 EPS for the quarter, missing the analyst consensus estimate by $ -0.03 based on the information available during the earnings call on Aug 3, 2016. Analyst had a consensus of $-0.33. The company had revenue of $32.77 million for the quarter, compared to analysts expectations of $29.36 million. The company’s revenue was up 44.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.40 EPS.
Nektar Therapeutics closed down -0.68 points or -3.77% at $17.35 with 67,99,124 shares getting traded on Tuesday. Post opening the session at $18.55, the shares hit an intraday low of $15.88 and an intraday high of $18.76 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
In a different news, on Sep 19, 2016, Lutz Lingnau (director) sold 9,000 shares at $19.06 per share price. According to the SEC, on Sep 19, 2016, Christopher A Kuebler (director) sold 7,500 shares at $19.13 per share price. On Sep 19, 2016, Robert Chess (director) sold 12,000 shares at $19.21 per share price, according to the Form-4 filing with the securities and exchange commission.
Nektar Therapeutics is a clinical-stage biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms which are designed to enable the development of new molecular entities that target known mechanisms of action. The Companys pipeline is comprised of drug candidates for therapeutic areas including oncology pain anti-infectives and immunology. The Companys research and development activities involve small molecule drugs peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics pharmacodynamics half-life bioavailability metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient. Its polymer chemistry platform is being used to create specialized therapeutics including small molecule oral and parenteral drugs proteins peptides and antibody fragments.